Zejula-话题@MedSci

#Zejula#

8篇内容 | 1023人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1734748, encodeId=d6fd1e347482d, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, objectType=article, longId=193374, objectId=b40b1933e4d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b1933e4d3, replyNumber=0, likeNumber=80, createdTime=2020-06-11, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b1933e4d3, moduleTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40b1933e4d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734745, encodeId=33031e347451e, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, objectType=article, longId=181868, objectId=ccf018186817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf018186817, replyNumber=0, likeNumber=70, createdTime=2020-09-10, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf018186817, moduleTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf018186817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734743, encodeId=26521e3474378, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, objectType=article, longId=180570, objectId=29001805e099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29001805e099, replyNumber=0, likeNumber=77, createdTime=2020-02-09, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29001805e099, moduleTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29001805e099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734747, encodeId=5a6b1e347473a, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=71, createdTime=2021-01-14, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734746, encodeId=c5f31e3474696, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, objectType=article, longId=185399, objectId=b7f018539947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f018539947, replyNumber=0, likeNumber=59, createdTime=2020-05-09, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f018539947, moduleTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f018539947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734744, encodeId=c9fd1e347449e, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！, objectType=article, longId=180817, objectId=185018081e44, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185018081e44, replyNumber=0, likeNumber=69, createdTime=2019-10-12, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185018081e44, moduleTitle=强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185018081e44)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734742, encodeId=e3761e3474224, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=Zejula显著延长卵巢癌患者的无进展生存期, objectType=article, longId=175550, objectId=7f621e55508b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f621e55508b, replyNumber=0, likeNumber=74, createdTime=2020-04-07, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f621e55508b, moduleTitle=Zejula显著延长卵巢癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f621e55508b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734741, encodeId=31291e3474165, content=<a href='/topic/show?id=4eb91901934' target=_blank style='color:#2F92EE;'>#Zejula#</a>, objectTitle=Tesaro的卵巢癌药物Zejula加入了癌症药物基金, objectType=article, longId=139764, objectId=89fe139e645d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fe139e645d, replyNumber=0, likeNumber=71, createdTime=2019-01-25, rootId=0, userName=sunylz, userId=8f9c33811778, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fe139e645d, moduleTitle=Tesaro的卵巢癌药物Zejula加入了癌症药物基金, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fe139e645d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Zejula

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#Zejula#

FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗

2020-06-11

sunylz (审核中...)

前往app查看评论内容

#Zejula#

美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗

2020-09-10

sunylz (审核中...)

前往app查看评论内容

#Zejula#

2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌

2020-02-09

sunylz (审核中...)

前往app查看评论内容

#Zejula#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2021-01-14

sunylz (审核中...)

前往app查看评论内容

#Zejula#

中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗

2020-05-09

sunylz (审核中...)

前往app查看评论内容

#Zejula#

强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！

2019-10-12

sunylz (审核中...)

前往app查看评论内容

#Zejula#

Zejula显著延长卵巢癌患者的无进展生存期

2020-04-07

sunylz (审核中...)

前往app查看评论内容

#Zejula#

Tesaro的卵巢癌药物Zejula加入了癌症药物基金

2019-01-25

科室
- - 订阅+
  - 更多科室
工具
服务